Welcome to our dedicated page for Bruker SEC filings (Ticker: BRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bruker Corporation (Nasdaq: BRKR) SEC filings page provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K, annual reports on Form 10-K, quarterly reports on Form 10-Q, and other key documents. These filings offer detailed information on Bruker’s financial condition, operating performance, capital structure, and material corporate events.
Bruker’s Form 8-K filings illustrate how the company reports significant developments such as quarterly and interim financial results, material modifications to security holder rights, and securities offerings. For example, Bruker has filed 8-Ks to furnish press releases with results of operations and financial condition for specific quarters, and to describe the issuance and terms of its 6.375% Mandatory Convertible Preferred Stock, Series A. That filing outlines the preferred stock’s dividend rate, liquidation preference, conversion mechanics into common stock, and related restrictions on dividends and share repurchases affecting junior and parity stock.
Through Forms 10-K and 10-Q, users can review segment information for Bruker Scientific Instruments and the Bruker Energy & Supercon Technologies (BEST) division, along with discussions of markets served, risk factors, and management’s analysis of results. These filings also describe how Bruker’s scientific instruments and diagnostic solutions support life science, applied, biopharma, industrial and cleantech research, and semiconductor metrology applications.
On this page, Stock Titan enhances Bruker’s raw SEC filings with AI-powered summaries that explain complex sections in plain language. Users can quickly understand the implications of Bruker’s 10-K and 10-Q reports, preferred stock terms, and other material events, while still having direct access to the original EDGAR documents. Filings related to insider transactions on Form 4 and proxy materials on Schedule 14A can also be monitored to track executive equity activity and governance matters over time.
Bruker Corporation reported Q3 2025 results showing total revenue of $860.5 million, slightly below last year’s $864.4 million. A $96.5 million goodwill impairment and higher cost of product revenue drove an operating loss of $51.8 million versus income of $68.1 million a year ago. Net loss attributable to common shareholders was $62.4 million (basic and diluted $(0.41) per share).
Year‑to‑date, operating cash flow was $(95.7) million. The company strengthened liquidity with net proceeds of $669.5 million from issuing 6.375% Series A Mandatory Convertible Preferred Stock. Cash and cash equivalents rose to $293.1 million as of September 30, 2025, while long‑term debt was $1.98 billion. Bruker completed acquisitions including Recipe Chemicals + Instruments, with 2025 acquired businesses contributing $11.5 million of revenue and $2.2 million of pre‑tax losses. Total shareholders’ equity increased to $2.45 billion. Common shares outstanding were 151,941,144 as of October 30, 2025.
Bruker Corporation furnished an update on its financial performance by announcing a press release with results for the three and nine months ended September 30, 2025. The press release, dated November 3, 2025, is provided as Exhibit 99.1.
The company states this information is being furnished under Item 2.02 and is not deemed “filed” for liability purposes, nor incorporated by reference unless expressly stated. The filing also includes a cautionary note regarding forward‑looking statements tied to the press release.
FMR LLC and Abigail P. Johnson report beneficial ownership of 17,082,319.90 shares of Bruker Corporation common stock, representing 11.0% of the outstanding class. The filing, a Schedule 13G/A, indicates these shares are held in the ordinary course of business and not for the purpose of changing control. The report shows FMR LLC with 13,832,390.78 shares of sole voting power and 17,082,319.90 shares of sole dispositive power; Abigail P. Johnson is reported with sole dispositive power over 17,082,319.90 shares and no voting power. The filing references an event date of 09/30/2025 and is signed on 10/06/2025. An Exhibit 99 agreement is attached per the document.
Bruker Corporation (BRKR) filed a Current Report disclosing arrangements for a new 6.375% Mandatory Convertible Preferred Stock, Series A. The filing lists an Underwriting Agreement dated September 3, 2025 with J.P. Morgan Securities LLC and BofA Securities, Inc. as representatives of the underwriters, a Certificate of Designations and the form of preferred stock certificate, and a legal opinion and consent from Simpson Thacher & Bartlett LLP dated September 8, 2025 regarding the legality of the shares. The exhibit index indicates these documents are attached, but the filing text does not state offering size, pricing, conversion terms, expected use of proceeds, or other economic details.
Bruker Corporation is offering 2,400,000 shares of 6.375% Mandatory Convertible Preferred Stock, Series A with a $250.00 liquidation preference per share and cumulative dividends payable quarterly beginning December 1, 2025 through September 1, 2028. Each preferred share will automatically convert on or about September 1, 2028 into between 6.9534 and 8.5179 shares of common stock based on a 20-trading-day Average VWAP during a defined Settlement Period, with holder early-conversion rights and special conversion mechanics upon certain Fundamental Changes. Bruker intends to list the securities on Nasdaq under the symbol BRKRP and expects to use net proceeds to repay indebtedness under specified facilities. The prospectus highlights structural subordination to indebtedness, anti-dilution adjustments, dividend-payment mechanics (including payments in cash or common stock valued at 97% of certain VWAP measures), a dividend stopper limiting common-stock distributions while preferred remains outstanding, and lock-up and underwriting arrangements. Investors are directed to the incorporated Risk Factors and related SEC filings for full detail.
Bruker Corporation is offering 2,400,000 shares of Mandatory Convertible Preferred Stock, Series A with a $250.00 per-share liquidation preference. Dividends are cumulative and payable when declared on specified quarterly Dividend Payment Dates beginning December 1, 2025 and ending September 1, 2028, and may be paid in cash, common stock or combination. Each preferred share will automatically convert around September 1, 2028 into a variable number of common shares based on the Average VWAP during a defined 20-Trading-Day Settlement Period, subject to Minimum and Maximum Conversion Rates and anti-dilution adjustments; holders also have limited early conversion rights, including upon a Fundamental Change. The company intends to list the preferred on Nasdaq under BRKRP; common stock trades under BRKR (last reported sale $33.98 on August 29, 2025). Net proceeds are intended to repay specified indebtedness to strengthen the balance sheet; affiliates of J.P. Morgan Securities LLC and BofA Securities, Inc. are expected to receive more than 5% of net proceeds. The prospectus references material risks, ranking and structural subordination to indebtedness and subsidiaries' liabilities.
Bruker Corporation director and President & CEO Frank H. Laukien reported transactions on 08/15/2025. He received 48,431 shares of Common Stock via restricted stock units (RSUs) at no cash cost, bringing his reported direct beneficial ownership to 38,494,103 shares. The RSUs vest in four equal annual installments beginning one year after the grant.
He also was granted a stock option to purchase 137,339 shares with a $36.872 exercise price; the option vests in four equal annual installments starting 08/15/2026 and expires 08/15/2030. The filing lists several indirect holdings: 1,055,639 shares by a former spouse, 337,087 by a son, 336,607 by a daughter, and additional custodial holdings described in the form.
Busse Falko, identified as President, Biospin Group and a director/officer of Bruker Corporation (BRKR), reported equity awards granted on 08/15/2025. The filing shows 9,282 restricted stock units (RSUs) were acquired at no cash price and 8,774 stock options were granted with a $33.52 exercise price. The RSUs vest in equal installments on the first four anniversaries of the original grant date and the options vest on the same four-year schedule; the options are exercisable beginning 08/15/2026 and expire 08/15/2035. Following the reported transactions, the reporting person beneficially owns 48,171 shares of common stock and 8,774 shares underlying options. The form was signed by an attorney-in-fact on 08/19/2025.
Bruker Corporation (BRKR) reporting person Mark Munch, Executive Vice President & President of Bruker Nano Inc., received equity awards on August 15, 2025. The filing shows 23,631 restricted stock units granted and 22,337 stock options with an exercise price of $33.52. The restricted stock units vest in four equal annual installments beginning one year after the original grant date, and the stock options vest on the same four‑year schedule with an exercisability starting 08/15/2026 and expiration on 08/15/2035. After the reported transactions, Mr. Munch beneficially owns 128,443 common shares and directly holds the 22,337 shares underlying the new options.
Bruker Corporation (BRKR) reported equity awards to Executive Vice President and CFO Gerald N. Herman on 08/15/2025 consisting of 25,844 Restricted Stock Units and 24,430 stock options with an exercise price of $36.872. Following the transactions Herman beneficially owns 102,583 shares and 24,430 options. Both the RSUs and the options vest in equal installments on each of the first four anniversaries of the original grant date, and the options become exercisable beginning 08/15/2026 with an expiration date of 08/15/2035. The transactions were reported on a Form 4 under Section 16.